ABOUT ICRF

THE ANSWER TO CANCER IS RESEARCH

SEE OUR WEBSITE

We harness the knowledge, educational resources, and research of Israel's best and brightest scientists in order to save the lives of cancer patients world wide.


Two of our very own ICRF-funded scientists (Professors Avram Hershko and Aaron Ciechanover of the Technion-Israel Institute of Technology) were nominated for and received the 2004 Nobel Prize in chemistry.


To date, ICRF has contributed more than USD $100,000,000 for over 3,000 grants involving all major hospitals, universities and cancer research projects throughout Israel.

OUR SUCCESSES

Gleevec® 

The development of Gleevec (imatinib) marked a turning point in cancer care, transforming chronic myelogenous leukemia into a manageable disease for more than 200,000 people worldwide.


P53 Gene

p53, known as the “guardian of the genome,” stands as one of the most important scientific discoveries of the 20th century, with mutations found in approximately 50% of all human tumors.


Ubiquitin System

The groundbreaking discovery of the ubiquitin–proteasome system led to Velcade, a transformative treatment for multiple myeloma, and was recognized with the 2004 Nobel Prize in Chemistry.


Doxil®

The first liposomal (fat-encapsulated) chemotherapy agent, offering longer circulation and reduced toxicity. It is now used in treating ovarian cancer, AIDS-related Kaposi’s sarcoma, and other cancers.


Gleevec® 


The development of Gleevec (imatinib) marked a turning point in cancer care, transforming chronic myelogenous leukemia into a manageable disease for more than 200,000 people worldwide.

P53 Gene


p53, known as the “guardian of the genome,” stands as one of the most important scientific discoveries of the 20th century, with mutations found in approximately 50% of all human tumors.

Ubiquitin System


The groundbreaking discovery of the ubiquitin–proteasome system led to Velcade, a transformative treatment for multiple myeloma, and was recognized with the 2004 Nobel Prize in Chemistry.


Doxil®


The first liposomal (fat-encapsulated) chemotherapy agent, offering longer circulation and reduced toxicity. It is now used in treating ovarian cancer, AIDS-related Kaposi’s sarcoma, and other cancers.


WHY ICRF?

Your Gift Goes Further

Research in Israel carries less overhead than North American research & funds are allocated directly to our scientists in their labs.

Startup Nation

Israel is a global powerhouse for innovation and entrepreneurialism.

Diversified Research

ICRF is currently funding 71 researchers across 11 institutions in Israel working on all areas of cancer research.